December 22, 2025

FDA Approves New Treatment for Lung Fibrosis

Nerandomilast becomes first preferential PDE4B inhibitor approved for PPF, slowing FVC decline in phase 3 trial

Conexiant

December 18, 2025

Top 10 States to Practice Pulmonology

The following list highlights the states that offer the most favorable conditions for pulmonologists.

Conexiant

December 17, 2025

Lung Cancer Screening Follow-up Shows Gaps

Investigators highlight disparities in diagnostic follow-up intensity after abnormal lung cancer screening findings across Lung Imaging Reporting and Data System categories using a national analysis of registry-linked Medicare data.

Conexiant

December 12, 2025

Help Needed. Help Avoided. Here’s Why.

Many older Americans qualify for disability accommodations but reject the label — limiting access to care, support, and legal protections.

KFF Health News

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

November 26, 2025

Chronic Cough Linked to GLP-1 Agonists 

New research suggests popular diabetes and weight-loss drugs may trigger persistent respiratory symptoms beyond their known gastrointestinal effects.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant

May 30, 2025

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.

Conexiant